147 related articles for article (PubMed ID: 10371596)
21. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.
Leung AY; Chow HC; Kwong YL; Lie AK; Fung AT; Chow WH; Yip AS; Liang R
Blood; 2001 Oct; 98(8):2584-7. PubMed ID: 11588061
[TBL] [Abstract][Full Text] [Related]
22. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
[TBL] [Abstract][Full Text] [Related]
23. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
Miners J
Pharmacogenetics; 2002 Mar; 12(2):91-2. PubMed ID: 11875362
[No Abstract] [Full Text] [Related]
24. Genetic control of anticoagulation.
Mannucci PM
Lancet; 1999 Feb; 353(9154):688-9. PubMed ID: 10073506
[No Abstract] [Full Text] [Related]
25. Genetic susceptibility to hemorrhagic complications during warfarin therapy.
Tabrizi AR; Freeman BD; Buchman TG; Zehnbauer BA
Surgery; 2001 May; 129(5):645-6. PubMed ID: 11331459
[No Abstract] [Full Text] [Related]
26. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
Lee CR; Goldstein JA; Pieper JA
Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
[TBL] [Abstract][Full Text] [Related]
27. [Clinical value of allele variants of cytochrome CYP2C9 gene for anticoagulation therapy with warfarin].
Sirotkina OV; Ulitina AS; Taraskina AE; Kadinskaia MI; Vavilova TV; Pchelina SN; Shvarts EI
Kardiologiia; 2005; 45(4):61-3. PubMed ID: 15940194
[TBL] [Abstract][Full Text] [Related]
28. Major bleeding caused by warfarin in a genetically susceptible patient.
Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y
Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436
[TBL] [Abstract][Full Text] [Related]
29. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
[No Abstract] [Full Text] [Related]
30. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
Borlak J; Thum T
Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
[No Abstract] [Full Text] [Related]
31. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
Hanatani T; Fukuda T; Ikeda M; Imaoka S; Hiroi T; Funae Y; Azuma J
Pharmacogenomics J; 2001; 1(4):288-92. PubMed ID: 11908770
[TBL] [Abstract][Full Text] [Related]
32. Genetic analysis of CYP2C9 polymorphism in a Japanese population.
Nasu K; Kubota T; Ishizaki T
Pharmacogenetics; 1997 Oct; 7(5):405-9. PubMed ID: 9352578
[No Abstract] [Full Text] [Related]
33. Pharmacogenetics of warfarin elimination and its clinical implications.
Takahashi H; Echizen H
Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
[TBL] [Abstract][Full Text] [Related]
34. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.
Yasar U; Eliasson E; Dahl ML
Carcinogenesis; 2002 Apr; 23(4):665; author reply 667-8. PubMed ID: 11960920
[No Abstract] [Full Text] [Related]
35. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.
Henne KR; Gaedigk A; Gupta G; Leeder JS; Rettie AE
J Chromatogr B Biomed Sci Appl; 1998 Jun; 710(1-2):143-8. PubMed ID: 9686881
[TBL] [Abstract][Full Text] [Related]
36. Genetic association between sensitivity to warfarin and expression of CYP2C9*3.
Steward DJ; Haining RL; Henne KR; Davis G; Rushmore TH; Trager WF; Rettie AE
Pharmacogenetics; 1997 Oct; 7(5):361-7. PubMed ID: 9352571
[TBL] [Abstract][Full Text] [Related]
37. Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms.
Tabrizi AR; McGrath SD; Blinder MA; Buchman TG; Zehnbauer BA; Freeman BD
Am J Hematol; 2001 Jun; 67(2):144-6. PubMed ID: 11343389
[TBL] [Abstract][Full Text] [Related]
38. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC
Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359
[TBL] [Abstract][Full Text] [Related]
39. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
40. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
